Two cases of imatinib induced oral pigmentation affecting the palate.
Medication related oral pigmentation is a unique yet benign finding in the dental setting. As new antineoplastic agents emerge, it is likely that this documented manifestation will continue to grow. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - March 23, 2024 Category: ENT & OMF Authors: Jenna Marcinczyk, Jason Portnof, Veronica Barreto, Paul Freedman, Renee Reich, Stanley Kerpel Source Type: research
The role of molecular or cytogenetic response as a favorable prognostic factor before hematopoietic stem cell transplantation for chronic myeloid leukemia
The discovery of tyrosine kinase inhibitors (TKIs) in the late 1990s revolutionized the treatment of patients with chronic myeloid leukemia (CML)1,2. Following the emergence of new TKIs, more recent studies have shown a life expectancy similar to that of the general population, making it possible to discontinue medication to reach the new milestone of treatment-free remission3,4. However, resistance to imatinib can occur in 10-15% of patients on first-line treatment and in approximately 10% of those on second-generation inhibitors5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2024 Category: Hematology Authors: Giuliana Rosendo de Oliveira Medeiros, Vaneuza Ara újo Moreira Funke, Alberto Cardoso Martins Lima, Ana Lúcia Vieira Mion, Isabela Menezes, Daniela Carinhanha Setubal, Caroline Bonamin dos Santos Sola, Gláucia Tagliari, Rafael Marchesini, Samir Kanaan Source Type: research
Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research
Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research
Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort
This study examines demographic, pharmacological, and genetic factors associated with impaired longitudinal growth in a uniform pediatric cohort treated with imatinib. We analyzed 94 pediatric patients with chronic myeloid leukemia (CML) diagnosed in the chronic phase and treated with imatinib for >12 months who participated in the Germany-wide CML-PAEDII study between February 2006 and February 2021. During imatinib treatment, significant height reduction occurred, with medians of -0.35 standard deviation score (SDS) at 12 months and -0.76 SDS at 24 months. Cumulative height SDS change (Δheight SDS) showed a more pron...
Source: Haematologica - March 18, 2024 Category: Hematology Authors: Sophie Stiehler Stephanie Sembill Oliver Schleicher Michaela Marx Manfred Rauh Manuela Krumbholz Axel Karow Meinolf Suttorp Joachim Woelfle Carlo Maj Markus Metzler Source Type: research
The first case of six-way complex translocation of t(4;7;9;22;8;14) in a patient with chronic myeloid leukemia
AbstractIn chronic myeloid leukemia (CML), patients exhibit the t(9;22)(q34.1;q11.2) translocation, resulting in the formation of a Philadelphia chromosome (Ph). However, a subset of CML patients display variant complex translocations, characterized by three-way, four-way, and five-way translocations, which have been occasionally associated with a poor prognosis. This case report presents the first case of a t(9;22) variant six-way complex translocation in CML. The R banding chromosome karyotyping technique was used to obtain preliminary karyotyping results, and the multi-probe FISH technique was used to assist in the veri...
Source: Journal of Hematopathology - March 16, 2024 Category: Pathology Source Type: research
[Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB ‑152 < em > in vivo < /em > and < em > in vitro < /em > by inhibiting the PI3K/AKT/mTOR signaling pathway
Oncol Rep. 2024 May;51(5):66. doi: 10.3892/or.2024.8725. Epub 2024 Mar 15.ABSTRACTFollowing the publication of the above article, a concerned reader drew to the Editor's attention that the Transwell cell invasion assay data featured in Figs. 2D and 4E, certain of the tumor images in Fig. 5A and the TUNEL assay data in Fig. 5C were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had either already been published elsewhere prior to the submission of this paper to Oncology Reports, or which under consideration for publication at around...
Source: Oncology Reports - March 15, 2024 Category: Cancer & Oncology Authors: Zhi Teng Shijuan Xu Qin Lei Source Type: research
[Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB ‑152 < em > in vivo < /em > and < em > in vitro < /em > by inhibiting the PI3K/AKT/mTOR signaling pathway
Oncol Rep. 2024 May;51(5):66. doi: 10.3892/or.2024.8725. Epub 2024 Mar 15.ABSTRACTFollowing the publication of the above article, a concerned reader drew to the Editor's attention that the Transwell cell invasion assay data featured in Figs. 2D and 4E, certain of the tumor images in Fig. 5A and the TUNEL assay data in Fig. 5C were strikingly similar to data appearing in different form in other articles written by different authors at different research institutes that had either already been published elsewhere prior to the submission of this paper to Oncology Reports, or which under consideration for publication at around...
Source: Oncology Reports - March 15, 2024 Category: Cancer & Oncology Authors: Zhi Teng Shijuan Xu Qin Lei Source Type: research
